November 4, 2025
Video: Innovation in Ocular Oncology
Investigational technologies and Protocol AL may help redefine what’s possible for patients with intraocular tumors, says Prithvi Mruthyunjaya, MD, MHS.
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/flcc2t52/1125-cover-final.jpg
Ophthalmology Management
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/43vf3gam/cover_oct25_web.jpg
Retinal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/kizp3ecu/1125-gp-cover-web.jpg
Glaucoma Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/0jsmmz3o/op_1025_cover_final.jpg
Ophthalmic Professional
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/jdnlmuh3/1025-oasc-cover-final.jpg
The Ophthalmic ASC
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/aqbjxwjw/pp-cover.jpg
Presbyopia Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/npjdtl1w/cp_november_cover.jpg
Corneal Physician
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/mvqdq2hc/nrp_cover_october_2024.jpg
New Retinal Physician
November 4, 2025
Investigational technologies and Protocol AL may help redefine what’s possible for patients with intraocular tumors, says Prithvi Mruthyunjaya, MD, MHS.
By Diana V. Do, MD, Prithvi Mruthyunjaya, MD, MHS
November 4, 2025
Audina M. Berrocal, MD, discusses how innovations in cutters and fluidics are transforming retinal surgery.
By Diana V. Do, MD, Audina M. Berrocal, MD
November 4, 2025
Quan Dong Nguyen, MD, discusses how retina specialists can refine diagnostic accuracy, simplify testing, and use systemic therapies safely.
By Diana V. Do, MD, Quan Dong Nguyen, MD
October 31, 2025
Surgeons say efficiency and innovation can align quality care with financial sustainability.
By Jim Gallagher, senior managing editor
October 21, 2025
Data presented at AAO demonstrated longer injection intervals and improved visual outcomes in both treatment-naïve and treatment-experienced patients with wet AMD and DME.
By Diana V. Do, MD
October 21, 2025
Practical guidance for retina specialists on monitoring and treatment of retinopathy of prematurity.
By Darius M. Moshfeghi, MD, Diana V. Do, MD
October 21, 2025
During retina subspecialty day, Aleksandra V. Rachitskaya, MD, presented on the role of GLP-1 receptor agonists in diabetic retinopathy, as well as other diseases like glaucoma and AMD.
By Aleksandra V. Rachitskaya, MD, FASRS, Diana V. Do, MD
October 20, 2025
Data presented for the first time at AAO 2025 highlight vision gains and reduced retinal thickness in previously treated eyes using flexible aflibercept 8 mg dosing.
By Diana V. Do, MD
October 20, 2025
ASRS president-elect Gaurav Shah shares advice for early career retina specialists attending subspecialty day at AAO or other large meetings in ophthalmology.
By Gaurav K. Shah, MD, Diana V. Do, MD
October 19, 2025
At AAO 2025, Andrew Lee, MD, reviewed clinical and imaging strategies to differentiate retinal pathology from diseases affecting the optic nerve and visual pathway.
By Jim Gallagher, senior managing editor
October 19, 2025
During retina subspecialty day, Jennifer I. Lim, MD, reviewed extension study data for Vabysmo, Eylea HD, and Susvimo, and previewed several promising investigational agents.
By Jennifer I. Lim, MD, FARVO, FASRS, Diana V. Do, MD
October 19, 2025
Allen C. Ho, MD, FACS, discusses 3-year data from Nanoscope Therapeutics’ MCO-010 program in RP, as well as the potential of this optogenetic approach to treat a broad range of retinal degenerative diseases.
By Allen C. Ho, MD
October 19, 2025
Data from the STERILE and RELIEF trials, presented at AAO, suggest a novel antiseptic may improve the patient experience without compromising infection prevention.
By David Brown, MD, Diana V. Do, MD
October 19, 2025
Part one of the RIOJA trial reports no serious adverse events or dose-limiting toxicity.
By Jim Gallagher, senior managing editor
October 18, 2025
New data from the GATHER2 open-label extension, presented during retina subspecialty day at AAO, emphasizes the value of starting treatment early to preserve retinal tissue.
By Arshad M. Khanani, MD, MA, FASRS, Diana V. Do, MD
October 18, 2025
GUARD trial data presented at AAO show that adjunctive ADX-2191 is linked to reduced rates of hypotony and cystoid macular edema in PVR surgery.
By Jim Gallagher, senior managing editor
October 18, 2025
Findings presented at AAO 2025 demonstrated that treatment with ablation and anti-VEGF injections allowed patients to avoid radiation-related damage, with most maintaining 20/40 vision or better.
By Timothy G. Murray, MD, MBA, FACS
October 18, 2025
Two-year ALTITUDE data presented during AAO’s retina subspecialty day showed that the suprachoroidal anti-VEGF gene therapy achieved sustained DRSS gains with acceptable safety.
By Charles C. Wykoff, MD, PhD
October 18, 2025
During retina subspecialty day at AAO 2025, Anat Loewenstein, MD, outlined practical applications of home OCT.
By Anat Loewenstein, MD, MHA, Diana V. Do, MD
October 18, 2025
At AAO 2025, Christina Y. Weng, MD, MBA, shared practical strategies to reduce neck, back, and upper-body strain for retina specialists.
By Christina Y. Weng, MD, MBA, Diana V. Do, MD